Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Has Labor Support For Extended Biologics Exclusivity

Executive Summary

The Sheet Metal Workers' International Association labor union supports the 12-year data exclusivity for biologics embodied in Sen. Edward Kennedy's follow-on biologics bill

You may also be interested in...



If You Can't Beat 'Em … Hire 'Em? PhRMA Exec Is New GPhA CEO

Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.

Defense-to-Offense: PhRMA Readies to Protect Government Markets

White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.

Pfizer Policy Effort Adjusts To Obama Era: Adds Greg Simon, From Obama Transition

Pfizer is aligning its internal policy shop to get more in tune with Democratic Washington. The first major staff change is Greg Simon moving from Faster Cures advocacy group to become senior VP-worldwide policy.

Related Content

Topics

UsernamePublicRestriction

Register

PS050950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel